These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31848474)

  • 21. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.
    Schulberg J; De Cruz P
    Intern Med J; 2016 Mar; 46(3):266-73. PubMed ID: 26968595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intestinal immune response is regulated by gut microbe].
    Tanemoto S; Sujino T; Kanai T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(6):408-415. PubMed ID: 29367525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enteric microflora in inflammatory bowel disease patients].
    Rahmouni O; Dubuquoy L; Desreumaux P; Neut C
    Med Sci (Paris); 2016 Nov; 32(11):968-973. PubMed ID: 28008837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Innate Immune System in the Gastrointestinal Tract: Role of Intraepithelial Lymphocytes and Lamina Propria Innate Lymphoid Cells in Intestinal Inflammation.
    Montalban-Arques A; Chaparro M; Gisbert JP; Bernardo D
    Inflamm Bowel Dis; 2018 Jul; 24(8):1649-1659. PubMed ID: 29788271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.
    Yu LC
    J Biomed Sci; 2018 Nov; 25(1):79. PubMed ID: 30413188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity.
    Chen L; Collij V; Jaeger M; van den Munckhof ICL; Vich Vila A; Kurilshikov A; Gacesa R; Sinha T; Oosting M; Joosten LAB; Rutten JHW; Riksen NP; Xavier RJ; Kuipers F; Wijmenga C; Zhernakova A; Netea MG; Weersma RK; Fu J
    Nat Commun; 2020 Aug; 11(1):4018. PubMed ID: 32782301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Gut Microbiota in Inflammatory Bowel Disease.
    Sheehan D; Shanahan F
    Gastroenterol Clin North Am; 2017 Mar; 46(1):143-154. PubMed ID: 28164847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism at the centre of the host-microbe relationship.
    Maslowski KM
    Clin Exp Immunol; 2019 Aug; 197(2):193-204. PubMed ID: 31107965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota.
    Mavragani CP; Nezos A; Dovrolis N; Andreou NP; Legaki E; Sechi LA; Bamias G; Gazouli M
    Inflamm Bowel Dis; 2020 Sep; 26(10):1543-1553. PubMed ID: 32812029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?
    Shapiro JM; Cho JH; Sands BE; LeLeiko NS
    Clin Gastroenterol Hepatol; 2015 May; 13(5):842-6. PubMed ID: 25725444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease.
    Gonçalves P; Araújo JR; Di Santo JP
    Inflamm Bowel Dis; 2018 Feb; 24(3):558-572. PubMed ID: 29462379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrative view of microbiome-host interactions in inflammatory bowel diseases.
    Wlodarska M; Kostic AD; Xavier RJ
    Cell Host Microbe; 2015 May; 17(5):577-91. PubMed ID: 25974300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The resilience of the intestinal microbiota influences health and disease.
    Sommer F; Anderson JM; Bharti R; Raes J; Rosenstiel P
    Nat Rev Microbiol; 2017 Oct; 15(10):630-638. PubMed ID: 28626231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humans as holobionts: implications for prevention and therapy.
    van de Guchte M; Blottière HM; Doré J
    Microbiome; 2018 May; 6(1):81. PubMed ID: 29716650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota and inflammatory bowel disease: so far so gut!
    Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.
    Shamoon M; Martin NM; O'Brien CL
    Pharmacol Res; 2019 Oct; 148():104344. PubMed ID: 31400403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota Developments With Emphasis on Inflammatory Bowel Disease: Report From the Gut Microbiota for Health World Summit 2016.
    Eppinga H; Fuhler GM; Peppelenbosch MP; Hecht GA
    Gastroenterology; 2016 Aug; 151(2):e1-4. PubMed ID: 27371370
    [No Abstract]   [Full Text] [Related]  

  • 38. [The human gut microbiota].
    Knudsen JK; Bundgaard-Nielsen C; Hagstrøm S; Sørensen S; Leutscher P
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease.
    Hirata Y; Ihara S; Koike K
    Pharmacol Res; 2016 Nov; 113(Pt A):574-584. PubMed ID: 27702681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics, prebiotics and amelioration of diseases.
    Tsai YL; Lin TL; Chang CJ; Wu TR; Lai WF; Lu CC; Lai HC
    J Biomed Sci; 2019 Jan; 26(1):3. PubMed ID: 30609922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.